Allogenic platelet gel in the treatment of pressure sores: a pilot study

Abstract

Although platelet gel is considered one of the most popular tools in the treatment of chronic ulcers, current consensus on its use is not unanimous. A prospective randomised trial was carried out at the Plastic Surgery Unit of the 'Salvatore Maugeri' Foundation Hospital of Pavia (Italy). The study involved 13 patients affected by spinal cord injury with 16 pressure sores over a period of 20 months. The ulcer was considered the experimental unit of the study irrespective of the number of ulcers per patient. Each consecutive ulcer was randomised to be treated either with allogenic platelet gel or with current best practice approach to chronic wounds dressing protocol. At the end of the treatment 15 ulcers out of 16 improved clinically. No statistically significant difference was demonstrated in volume reduction between the two groups, although a statistically significant difference could be demonstrated in the onset time of granulation tissue proliferation as in the wounds treated with platelet gel the healing process was triggered earlier. Our study suggests that platelet gel is mostly effective within the first 2 weeks of treatment while a prolonged treatment does not provide any significant advantage versus the current best practice approach to chronic wounds protocols.

Role of local application of autologous platelet-rich plasma in the management of pressure ulcers in spinal cord injury patients

“…The present study corroborates the findings of the Rappl 5 who reported that most healing occurred in first 3-4 weeks of treatment, and also of Scevola et al 14 who reported that in subjects with SCI and deep PrUs , there was a statistically significant increase in the onset of the granulation phase of wound healing, the healing process was triggered faster and there was more healing in the first 2 weeks of treatment with allogenic PRP gel compared with 'current best-practice approach to chronic wound-dressing protocol' . It is generally accepted that platelet growth factors have a central role in the healing process and tissue formation.…”

“…3,5,[10][11][12][13][17][18][19] Only very few studies have evaluated its role in PrUs in the SCI population. 3,5,10,11,14 The purpose of the present prospective study was to evaluate the application of PRP in relation to PrUs healing on the basis of clinical, wound size measurement and histopathological features versus saline dressing on the other PrU in the same patient. There was statistically significant decrease in mean PUSH scores of PrUs (case) (t ¼ 6.13, Po0.000) and PrUs (control) (t ¼ 3.98, P ¼ 0.000) after 5 weeks.…”

“…[10][11][12][13] Authors have not come across any pre-clinical evidence of PRP in PrUs; however, recently few studies have shown usefulness of PRP in PrUs, as it leads to reactivation and accelerated healing in PrUs. 3,5,10,11,14 The purpose of the present prospective study was to evaluate the application of PRP in relation to PrUs healing on the basis of clinical, wound size measurement and histopathological features in one PrU (case) versus saline dressing on the another PrU (control) in the same patient.…”

Incorporating Platelet-Rich Plasma into Electrospun Scaffolds for Tissue Engineering Applications

“…While the use of pooled blood is typically frowned upon in the United States, the use of allogenic PRP has been gaining popularity in a number of European studies with no mention of adverse immune reactions. [53][54][55][56] FIG. 12.…”

Current Treatment Approaches in Pressure Ulcers

“…12 Otolog trombosit jel, yüksek miktarda büyüme faktörlerini içerdiğinden doku onarımı ve rejenerasyonunda belirgin bir hızlanma sağlamaktadır. 29 Eritropoietin mitozu stimüle edip, anjiyogenezi uyarır ve hemoglobin düzeyi-ni arttırarak doku oksijenizasyonunu arttırır. Böylece bası yarasının iyileşmesini hızlandırmaktadır.…”